Self-powered paper-based 'SPEDs' may lead to new medical-diagnostic tools

A new medical-diagnostic device made out of paper detects biomarkers and identifies diseases by performing electrochemical analyses - powered only by the user's touch - and reads out the color-coded test results, making it easy for non-experts to understand. The self-powered, paper-based electrochemical devices, or SPEDs, are designed for sensitive diagnostics at the "point-of-care," or when care is delivered to patients, in regions where the public has limited access to resources or sophisticated medical equipment.

"You could consider this a portable laboratory that is just completely made out of paper, is inexpensive and can be disposed of through incineration," said Ramses V. Martinez, an assistant professor of industrial and biomedical engineering at Purdue University. "We hope these devices will serve untrained people located in remote villages or military bases to test for a variety of diseases without requiring any source of electricity, clean water, or additional equipment."

"SPEDs are inexpensive, lightweight, flexible and easy to use," Martinez said.

Research findings are detailed in a paper appearing on Aug. 22 in Advanced Materials Technologies.

The test is initiated by placing a pinprick of blood in a circular feature on the device, which is less than two-inches square. SPEDs also contain "self-pipetting test zones" that can be dipped into a sample instead of using a finger-prick test.

The top layer of the SPED is fabricated using untreated cellulose paper with patterned hydrophobic "domains" that define channels that wick up blood samples for testing. These "micro?uidic channels" allow for accurate assays that change color to indicate specific testing results. A machine-vision diagnostic application also was created to automatically identify and quantify each of these "colorimetric" tests from a digital image of the SPED, perhaps taken with a cellphone, to provide fast diagnostic results to the user and to facilitate remote-expert consultation.

The bottom layer of the SPED is a "triboelectric generator," or TEG, which generates the electric current necessary to run the diagnostic test simply by rubbing or pressing it. The researchers also designed an inexpensive handheld device called a potentiostat, which is easily plugged into the SPED to automate the diagnostic tests so that they can be performed by untrained users. The battery powering the potentiostat can be recharged using the TEG built into the SPEDs.

"To our knowledge, this work reports the ?rst self-powered, paper-based devices capable of performing rapid, accurate, and sensitive electrochemical assays in combination with a low-cost, portable potentiostat that can be recharged using a paper-based TEG," Martinez said.

He co-authored the paper with graduate students Aniket Pal and Debkalpa Goswami; visiting scholars Hugo E. Cuellar and Heloisa F. N. Caurin; and Randy Kuang, a high school student who participated in the research.

The research paper describes the SPEDs, the portable potentiostat and a machine-vision algorithm that is able to recognize the color-coded information. SPEDs are compatible with mass-printing technologies, such as roll-to-roll printing or spray deposition. They can perform "multiplexed" analyses enabling the highly sensitive and accurate detection of various targets for a range of point-of-care testing applications. And they can be used to power other electronic devices to facilitate telemedicine applications in resource-limited settings.

The SPEDs were used to detect biomarkers such as glucose, uric acid and L-lactate, ketones, and white blood cells, which indicate factors related to liver and kidney function, malnutrition and anemia. Future versions of the technology will contain several additional layers for more complex assays to detect diseases such as dengue fever, yellow fever, malaria, HIV and hepatitis, Martinez said.

Aniket Pal, Hugo E Cuellar, Randy Kuang, Heloisa F N Caurin, Debkalpa Goswami, Ramses V Martinez.
Self-Powered, Paper-Based Electrochemical Devices for Sensitive Point-of-Care Testing.
Adv. Mater. Technol. 2017, 1700130. doi: 10.1002/admt.201700130.

Most Popular Now

Top 20 breaking World Pharma News of 2017

We are proud to announce the top 20 most popular breaking World Pharma News from 2017. Have a wonderful 2018 new(s) year filled with health, happiness, and spectacular su...

Novartis advances head-to-head superiority trials …

Novartis announced today the initiation of SURPASS, a head-to-head clinical trial of Cosentyx® (secukinumab) versus proposed biosimilar adalimumab** in ankylosing spondyl...

Diabetes drug 'significantly reverses memory loss…

A drug developed for diabetes could be used to treat Alzheimer's after scientists found it "significantly reversed memory loss" in mice through a triple method of action...

Sandoz regulatory submission for proposed biosimil…

Sandoz, a Novartis division and the global leader in biosimilar medicines, announced today that the US Food and Drug Administration (FDA) has accepted its Biologics Licen...

Zika remains a research and public health challeng…

Since 2016, when Zika was declared by the World Health Organization as a public health emergency of international concern, the virus has become established in more than 8...

Try exercise to improve memory, thinking

For patients with mild cognitive impairment, don't be surprised if your health care provider prescribes exercise rather than medication. A new guideline for medical pract...

New research paper shows that AstraZeneca has achi…

In a research paper published today by Nature Reviews Drug Discovery(1), AstraZeneca's IMED Biotech Unit documents a more than four-fold improvement in R&D productivity f...

Dirt-dwelling microbe produces potential anti-mela…

A type of soil-dwelling bacterium produces molecules that induce death in melanoma cells, research at Oregon State University shows. The molecule is a secondary metabolit...

Novartis Kisqali® received FDA Breakthrough Therap…

Novartis today announced Kisqali® (ribociclib) received US Food and Drug Administration (FDA) Breakthrough Therapy designation for initial endocrine-based treatment of pr...

FDA approves first treatment for breast cancer wit…

The U.S. Food and Drug Administration today expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast can...

Berry gives boost to cervical cancer therapy

According to the Centers for Disease Control and Prevention, approximately 12,000 women in the United States are diagnosed with cervical cancer each year. One of the most...

Novartis appoints Elizabeth Barrett as Oncology He…

Novartis announced today that Elizabeth (Liz) Barrett, currently Global President Oncology at Pfizer, Inc., has been appointed CEO Novartis Oncology and a member of the E...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]